Tagraxofusp
- Generic Name
- Tagraxofusp
- Brand Names
- Elzonris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2055491-00-2
- Unique Ingredient Identifier
- 8ZHS5657EH
- Background
Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli. Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for ...
- Indication
Tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). In the US, it is approved for use in adults and pediatric patients over 2 years old. In Europe, it is only approved for use in adults.
- Associated Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Associated Therapies
- First-line Therapy
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 20
- Registration Number
- NCT06561152
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 43
- Registration Number
- NCT06498973
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06456463
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇦🇺Royal Perth Hospital, Perth, Western Australia, Australia
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06414681
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 54
- Registration Number
- NCT05476770
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)
- Conditions
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Karen Ballen, MD
- Target Recruit Count
- 44
- Registration Number
- NCT05233618
- Locations
- 🇺🇸
Danyelle Coley, Charlottesville, Virginia, United States
Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT05038592
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05032183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2022-01-10
- Target Recruit Count
- 50
- Registration Number
- NCT04342962
- Locations
- 🇮🇹
Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia, Bologna, Italy
🇮🇹Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia, Bergamo, Italy
🇮🇹Asst Degli Spedali Civili Di Brescia - Uo Ematologia, Brescia, Italy
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.